Novartis (NVS) Tops Q2 EPS by 3c

Novartis (NYSE: NVS) reported Q2 EPS of $1.27, $0.03 better than the analyst estimate of $1.24. Revenue for the quarter came in at $12.7 billion versus the consensus estimate of $12.45 billion.

Outlook 2015 for continuing operations confirmed:

• Continuing operations net sales expected to grow mid-single digit (cc); core operating income expected to grow ahead of sales at a high-single digit rate (cc)
• To reflect first half performance, Novartis raises Sandoz FY guidance to high single digit sales growth (cc), lowers Alcon FY guidance to low single digit sales growth (cc)

For earnings history and earnings-related data on Novartis (NVS) click here.

You May Also Be Interested In

• Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
• Boardwalk REIT reports occupancy near 97%, $306M in 2026 asset sales
• Novartis wins EU approval for SMA gene therapy in older patients